News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
551,483 Results
Type
Article (46598)
Company Profile (119)
Press Release (504755)
Multimedia
Podcasts (142)
Webinars (19)
Section
Business (145726)
Career Advice (2419)
Deals (28113)
Drug Delivery (141)
Drug Development (68526)
Employer Resources (158)
FDA (15972)
Job Trends (12061)
News (265536)
Policy (29908)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2315)
Academic (1)
Accelerated approval (35)
Adcomms (36)
Allergies (137)
Alliances (36147)
ALS (163)
Alzheimer's disease (1711)
Antibody-drug conjugate (ADC) (315)
Approvals (16117)
Artificial intelligence (500)
Autoimmune disease (159)
Automation (33)
Bankruptcy (312)
Best Places to Work (9192)
BIOSECURE Act (23)
Biosimilars (191)
Biotechnology (69)
Bladder cancer (157)
Brain cancer (54)
Breast cancer (589)
Cancer (4540)
Cardiovascular disease (410)
Career advice (2046)
Career pathing (39)
CAR-T (260)
CDC (59)
Celiac Disease (1)
Cell therapy (723)
Cervical cancer (35)
Clinical research (58854)
Collaboration (1489)
Company closure (4)
Compensation (1156)
Complete response letters (74)
COVID-19 (2718)
CRISPR (88)
C-suite (786)
Cystic fibrosis (141)
Data (5789)
Decentralized trials (2)
Denatured (32)
Depression (144)
Diabetes (481)
Diagnostics (5540)
Digital health (38)
Diversity (7)
Diversity, equity & inclusion (43)
Drug discovery (221)
Drug pricing (221)
Drug shortages (33)
Duchenne muscular dystrophy (238)
Earnings (62301)
Editorial (67)
Employer branding (20)
Employer resources (142)
Events (81885)
Executive appointments (893)
FDA (19046)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (20)
Funding (1274)
Gene editing (194)
Generative AI (43)
Gene therapy (609)
GLP-1 (1067)
Government (4196)
Grass and pollen (8)
Guidances (376)
Healthcare (14883)
HIV (59)
Huntington's disease (49)
IgA nephropathy (86)
Immunology and inflammation (288)
Immuno-oncology (59)
Indications (100)
Infectious disease (2981)
Inflammatory bowel disease (182)
Inflation Reduction Act (14)
Influenza (109)
Intellectual property (236)
Interviews (453)
IPO (14133)
IRA (58)
Job creations (3173)
Job search strategy (1672)
JPM (67)
Kidney cancer (17)
Labor market (83)
Layoffs (618)
Leadership (40)
Legal (7015)
Liver cancer (90)
Longevity (12)
Lung cancer (599)
Lymphoma (355)
Machine learning (40)
Management (52)
Manufacturing (735)
MASH (168)
Medical device (11582)
Medtech (11626)
Mergers & acquisitions (14975)
Metabolic disorders (1318)
Multiple sclerosis (144)
NASH (22)
Neurodegenerative disease (323)
Neuropsychiatric disorders (98)
Neuroscience (2910)
Neurotech (1)
NextGen: Class of 2026 (4996)
Non-profit (3195)
Now hiring (31)
Obesity (661)
Opinion (277)
Ovarian cancer (153)
Pain (189)
Pancreatic cancer (219)
Parkinson's disease (275)
Partnered (26)
Patents (477)
Patient recruitment (461)
Peanut (54)
People (44198)
Pharmaceutical (33)
Pharmacy benefit managers (32)
Phase 1 (17659)
Phase 2 (25470)
Phase 3 (20862)
Pipeline (5011)
Policy (334)
Postmarket research (2210)
Preclinical (7141)
Press Release (28)
Prostate cancer (239)
Psychedelics (55)
Radiopharmaceuticals (244)
Rare diseases (884)
Real estate (4301)
Recruiting (65)
Regulatory (23188)
Reports (40)
Research institute (2115)
Resumes & cover letters (404)
Rett syndrome (27)
RNA editing (16)
RSV (73)
Schizophrenia (153)
Series A (216)
Series B (177)
Service/supplier (8)
Sickle cell disease (96)
Special edition (25)
Spinal muscular atrophy (139)
Sponsored (46)
Startups (2788)
State (1)
Stomach cancer (20)
Supply chain (104)
Tariffs (101)
The Weekly (109)
Vaccines (1098)
Venture capital (96)
Weight loss (466)
Women's health (75)
Worklife (22)
Date
Last 7 days (570)
Last 30 days (1859)
Last 365 days (28085)
2026 (3211)
2025 (28396)
2024 (31398)
2023 (34983)
2022 (45059)
2021 (48499)
2020 (45516)
2019 (36221)
2018 (27409)
2017 (27814)
2016 (25811)
2015 (27977)
2014 (21774)
2013 (17793)
2012 (18963)
2011 (19381)
2010 (17504)
Location
Africa (686)
Alabama (66)
Alaska (6)
Arizona (231)
Arkansas (10)
Asia (32361)
Australia (5669)
California (10423)
Canada (2511)
China (917)
Colorado (407)
Connecticut (459)
Delaware (304)
Europe (79010)
Florida (1579)
Georgia (318)
Hawaii (4)
Idaho (39)
Illinois (741)
India (54)
Indiana (425)
Iowa (22)
Japan (407)
Kansas (105)
Kentucky (25)
Louisiana (19)
Maine (73)
Maryland (1289)
Massachusetts (7544)
Michigan (266)
Minnesota (554)
Mississippi (5)
Missouri (118)
Montana (12)
Nebraska (22)
Nevada (111)
New Hampshire (60)
New Jersey (2806)
New Mexico (15)
New York (2696)
North Carolina (1349)
North Dakota (7)
Northern California (5175)
Ohio (279)
Oklahoma (15)
Oregon (34)
Pennsylvania (2000)
Puerto Rico (18)
Rhode Island (32)
South America (1045)
South Carolina (64)
South Dakota (1)
Southern California (4052)
Tennessee (151)
Texas (1552)
United States (36442)
Utah (262)
Virginia (243)
Washington D.C. (73)
Washington State (828)
West Virginia (4)
Wisconsin (110)
Wyoming (1)
551,483 Results for "pharmamar s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s disease
Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
February 9, 2026
·
4 min read
·
Annalee Armstrong
Alzheimer’s disease
In Novo’s GLP-1 Failure, Alzheimer’s Space Spies a Combination Opportunity
Despite the definitive failure of Novo Nordisk’s semaglutide in Alzheimer’s, biotech executives, analysts and other industry experts see potential in more testing of GLP-1s for the neurodegenerative disease, particularly in a combination approach.
January 2, 2026
·
5 min read
·
Annalee Armstrong
Alzheimer’s disease
Novartis Makes $1.5B+ Alzheimer’s Play With China’s SciNeuro
The deal will see Novartis gain global rights over SciNeuro’s potentially disease-modifying anti-amyloid antibody, which leverages the latter’s proprietary shuttle platform to allow delivery into the brain.
January 12, 2026
·
2 min read
·
Tristan Manalac
Vaccines
Flu Vaccine Rejection Imperils Moderna’s Breakeven Plans
Moderna’s mRNA-1010 was expected to contribute $1 billion to the company’s coffers by 2028. That plan is now out the window after the FDA refused to even look at the application.
February 12, 2026
·
4 min read
·
Dan Samorodnitsky
Parkinson’s disease
AC Immune’s Parkinson’s Immunotherapy Appears to Slow Disease Progression
In a first for the Parkinson’s field, AC Immune’s immunotherapy has stabilized key biomarkers that suggest an effect on the disease’s course.
December 11, 2025
·
1 min read
·
Annalee Armstrong
Collaboration
JPM26: BMS’s Early-Stage Bets Are Happening Now, Amid Pharma’s Late-Stage Frenzy
Mature biopharma deals are stealing all the headlines, but Bristol Myers Squibb’s Robert Plenge says the company’s deals with insitro, Orbital and more are building the future.
January 12, 2026
·
3 min read
·
Annalee Armstrong
Earnings
Pfizer’s Early Metsera Data Leaves Analysts Wanting More
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
February 3, 2026
·
4 min read
·
Annalee Armstrong
Podcast
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
The obesity market and Most Favored Nation drug pricing were among the topics de jour at the J.P. Morgan Healthcare Conference last week, while smaller biotechs sought to assure investors that their regulatory ducks are in a row; Novo Nordisk’s oral obesity pill got off to a hot start while the FDA delayed a decision on Eli Lilly’s investigational offering; and SpyGlass Pharma and AgomAb Therapeutics join the 2026 IPO club.
January 21, 2026
·
1 min read
·
Heather McKenzie
Podcast
Lilly’s Triple Triumph, Prasad’s COVID Error, J&J’s Surprise Voucher, M&A Targets
Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal FDA safety review finds no confirmed pediatric deaths caused by COVID-19 vaccines, and Commissioner Marty Makary says no black box warning will be attached to the shots; and BioSpace looks at six biotechs that could be pharma’s next buy.
December 17, 2025
·
2 min read
·
Heather McKenzie
FDA
Moderna’s Outright Flu Refusal Just the Latest Case of Crossed FDA Signals
The FDA’s refusal to review Moderna’s mRNA-based flu vaccine is part of a larger communications crisis unfolding at the agency over the past nine months that has also ensnarled Sarepta, Capricor, uniQure and many more.
February 13, 2026
·
6 min read
·
Heather McKenzie
1 of 55,149
Next